Kidney biomarkers and decline in eGFR in patients with type 2 diabetes
Clinical Journal of the American Society of Nephrology Mar 30, 2018
Garlo KG, et al. - The link between kidney biomarkers [serum cystatin C, urinary kidney injury molecule–1 (uKIM-1), and urinary neutrophil gelatinase-associated lipocalin (UNGAL)] and decline in eGFR was assessed in individuals with type 2 diabetes mellitus and recent acute coronary syndromes enrolled in the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial. In this patient population, eGFR decline prediction did not meaningfully improve by adding cystatin C or biomarkers of tubular injury, beyond common clinical factors and routine laboratory data.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries